News for InflaRx N.V. (IFRX)

InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its Phase 3 trial for vilobelimab in pyoderma gangrenosum/PG would be discontinued due to futility. The recommendation came from the Independent Data Monitoring Committee/IDMC after an unblinded interim analysis of data from the […]

InflaRx (IFRX) recently disclosed that it has received notification from Nasdaq regarding non-compliance with the minimum bid price requirement. For the past 30

JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the 'Notice”), dated July 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ('Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the 'Minimum Bid Price Rule”).

JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.25% to 42,237.69 while ...

U.S. stocks traded higher this morning, with the Dow Jones index jumping around 100 points on Wednesday. Following the market opening Wednesday, the Dow traded...

Shares of Box, Inc. BOX rose sharply in today's pre-market trading after the company posted better-than-expected first-quarter results and raised its FY2026 gui...

**media[638695]**

JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. ( IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the c

InflaRx (IFRX) to present at three major investor conferences in June and July 2025. Lead product candidate vilobelimab is in focus, alongside the devel

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-ter

InflaRx (IFRX) reports a reduced net loss of €8.3 million for Q1 2025, improved from €9.7 million in Q1 2024. The company raised €28.7 million thr

JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. ( IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the

InflaRx (IFRX) to announce Q1 2025 financial results on May 7, 2025, before market opens. No earnings call is scheduled, limiting direct investor intera

InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-

JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. ( IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the co

**media[553509]**